

Study tests

At regular study center visits, you will also have various study tests and assessments to check on your health and how you are responding to the study treatment. These include the following:



Collection of blood samples to check your overall health and your body's response to study treatment



Measurement of your blood pressure, temperature, pulse rate, and breathing rate



Completing questionnaires about how gMG affects your life



Recording of your heart's electrical activity by conducting an electrocardiogram (ECG) test



Tests to check your muscle strength

No study tests or assessments will take place until you have given your informed consent.

Get in touch

For further information and to find out if you could be part of the ETNA Study, contact the study team:



The Neurology Clinic



901-866-9252



Research@neuroloclinic.org

A member of the study team will be pleased to talk through the study in more detail with you. Contacting us does not mean that you must or will be able to take part.



www.xxxxxxxxxxxxxx.com



Participation in the study is entirely voluntary. If you choose not to take part or you leave the study, it will not affect your standard medical care.

**Determination
to transform the
myasthenia gravis
treatment landscape**

Study Information Brochure



What are clinical studies?

Clinical research studies help scientists and doctors explore whether an investigational drug is safe and whether it works. Before a doctor is allowed to prescribe a new treatment, it must go through several phases of clinical research.

“Investigational” means that health and regulatory authorities have not approved it for public use (in your locality). It can only be used in clinical studies such as this one.

What is the ETNA Study?

The **ETNA Study** is evaluating the safety and tolerability (how well your body handles) of an investigational drug, called povetacicept, in adults living with **generalized myasthenia gravis (gMG)**.

In gMG, the body’s own immune system mistakenly attacks the connections between nerves and muscles. This leads to muscle weakness and fatigue. Povetacicept might block two proteins (BAFF and APRIL) that are involved with inflammation and associated with gMG.

In some parts of this study, povetacicept will be compared with a placebo. A placebo looks like the investigational drug but does not contain any medically active ingredients.

How is study treatment given?

The study treatment (povetacicept or placebo) is given once every 4 weeks as an injection under the skin in the arm, thigh, or belly.

Will I receive the investigational drug?

In the main study treatment period, there is a 2 in 3 (67%) chance of receiving povetacicept and a 1 in 3 (33%) chance of receiving placebo. In an **optional** extension period, all participants receive povetacicept.

If you have been taking standard medications to control your gMG symptoms, you will likely be able to continue to take these while you are participating in the study.

Who can take part?

You may be able to take part in the study if you:



Are **between 18 and 80 years** of age



Have been **diagnosed with gMG**

Study design

SCREENING: Up to 1 month

One study center visit with various assessments to evaluate if the study is a good fit for you



STUDY TREATMENT: 3 months

Receive assigned study treatment at 3 visits (4 weeks apart) at the study center



OPTIONAL EXTENSION: Up to 22 months

Receive povetacicept every 4 weeks at the study center



SAFETY FOLLOW-UP

One study center visit around 12 weeks after your final dose of study treatment

